Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

EU approval for new asthma drug Exdensur lifts GSK

Summary by Pharmaphorum
EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur

3 Articles

PharmaphorumPharmaphorum
Center

EU approval for new asthma drug Exdensur lifts GSK

EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur

Read Full Article
pharmatimes.compharmatimes.com

Exdensur approved in EU for severe asthma and CRSwNP

European Commission backs first ultra‑long‑acting biologic for respiratory disease

Read Full Article
redaccionmedica.comredaccionmedica.com

Europe Approves Gsk Drug for Severe Asthma and Rhinosinusitis

GSK has announced that the European Commission (EC) has approved Exdensur (depemokimab) for two indications: Complementary maintenance treatment of severe asthma with type 2 inflammation characterized by elevated blood eosinophil counts in adults and adolescents aged 12 years and older who are insufficiently controlled despite the use of inhaled corticosteroids (CSI) at high doses plus another asthma controller. Complementary therapy with intran…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news in on Tuesday, February 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

European Union icon

European Union

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal